NCT00673218View on ClinicalTrials.gov

The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils

PHASE4UnknownINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Allergy

Interventions

DRUG

Placebo

Placebo, Q2 or 4 weeks depending on Ige level and weight as appropriate for active treatment.

DRUG

Xolair

150 to 375 mg is administered SC every 2 or 4 weeks

Trial Locations (1)

68131

Creighton University, Omaha

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

Creighton University

OTHER